| Company Name: |
LGM Pharma |
| Tel: |
1-(800)-881-8210 |
| Email: |
inquiries@lgmpharma.com |
|
| | Motavizumab Basic information |
| Product Name: | Motavizumab | | Synonyms: | MOTAVIZUMAB;Numax;Research Grade Motavizumab(DVV02803);Motavizumab (anti-RSV-F);Research Grade Motavizumab | | CAS: | 677010-34-3 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Motavizumab Structure]() |
| | Motavizumab Chemical Properties |
| storage temp. | Store at -20°C | | form | Liquid | | color | Colorless to light yellow |
| | Motavizumab Usage And Synthesis |
| Uses | Motavizumab can prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients at high risk of RSV disease. | | in vivo | Motavizumab (intraperitoneal injection; 1.25 mg in 0.1 ml of PBS/per mouse; once) treatment shows reductions on RSV replication and concentrations of cytokine and chemokines in RSV-infected mice[1]. | Animal Model: | Seven-week-old female, pathogen-free BALB/c mice intranasally inoculated with 106.5 PFU RSV-A2[1] | | Dosage: | 1.25 mg in 0.1 ml of PBS/per mouse | | Administration: | Intraperitoneal injection; 1.25 mg in 0.1 ml of PBS/per mouse; once | | Result: | Resulted in significant reductions of RSV loads compared with untreated controls on days 1 and 5.
Showed lower BAL concentrations of IL-1α, IL-12p70, TNF-α and IFN-γ and serum IL-10 and KC compared with RSV-infected untreated mice. |
|
| | Motavizumab Preparation Products And Raw materials |
|